According to a recent LinkedIn post from Inductive Bio, the company’s Compass platform ranked first among more than 370 teams in the OpenADMET competition, ahead of entries from Merck and EMD Serono. The post emphasizes that independent, benchmark-style evaluations may help drug discovery teams assess which AI tools perform reliably in real-world settings.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also notes that budget constraints can limit adoption of new technology and indicates that 37 drug discovery teams will be offered free access to Compass to evaluate its impact on active small-molecule programs. The post further references an upcoming OpenADMET webinar, which could serve as additional visibility for Inductive Bio’s approach and potentially support future commercial traction if users validate the platform’s utility.